The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.
Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.
A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.